Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

Daniela Dobre, Jeffrey S. Borer, Kim Fox, Karl Swedberg, Kirkwood F. Adams, John G F Cleland, Alain Cohen-Solal, Mihai Gheorghiade, Francois Gueyffier, Christopher M. O'Connor, Mona Fiuzat, Athul Patak, Ileana L. Pina, Giuseppe Rosano, Hani N. Sabbah, Luigi Tavazzi, Faiez Zannad

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (riskfactor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bra-dycardic agent.

Original languageEnglish (US)
Pages (from-to)76-85
Number of pages10
JournalEuropean Journal of Heart Failure
Volume16
Issue number1
DOIs
StatePublished - 2014

Fingerprint

ivabradine
Heart Failure
Heart Rate
Pharmaceutical Preparations
Amiodarone
Digoxin
Verapamil
Therapeutics
Pharmacology
Morbidity
Phenotype

Keywords

  • Amiodarone
  • Beta-blockers
  • Chronic heart failure
  • Digoxin
  • Heart rate
  • Heart rate-lowering drugs
  • Ivabradine
  • Verapamil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Heart rate : A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. / Dobre, Daniela; Borer, Jeffrey S.; Fox, Kim; Swedberg, Karl; Adams, Kirkwood F.; Cleland, John G F; Cohen-Solal, Alain; Gheorghiade, Mihai; Gueyffier, Francois; O'Connor, Christopher M.; Fiuzat, Mona; Patak, Athul; Pina, Ileana L.; Rosano, Giuseppe; Sabbah, Hani N.; Tavazzi, Luigi; Zannad, Faiez.

In: European Journal of Heart Failure, Vol. 16, No. 1, 2014, p. 76-85.

Research output: Contribution to journalArticle

Dobre, D, Borer, JS, Fox, K, Swedberg, K, Adams, KF, Cleland, JGF, Cohen-Solal, A, Gheorghiade, M, Gueyffier, F, O'Connor, CM, Fiuzat, M, Patak, A, Pina, IL, Rosano, G, Sabbah, HN, Tavazzi, L & Zannad, F 2014, 'Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties', European Journal of Heart Failure, vol. 16, no. 1, pp. 76-85. https://doi.org/10.1093/eurjhf/hft129
Dobre, Daniela ; Borer, Jeffrey S. ; Fox, Kim ; Swedberg, Karl ; Adams, Kirkwood F. ; Cleland, John G F ; Cohen-Solal, Alain ; Gheorghiade, Mihai ; Gueyffier, Francois ; O'Connor, Christopher M. ; Fiuzat, Mona ; Patak, Athul ; Pina, Ileana L. ; Rosano, Giuseppe ; Sabbah, Hani N. ; Tavazzi, Luigi ; Zannad, Faiez. / Heart rate : A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. In: European Journal of Heart Failure. 2014 ; Vol. 16, No. 1. pp. 76-85.
@article{e5318122488f45639d7e97cf0734a830,
title = "Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties",
abstract = "Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (riskfactor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bra-dycardic agent.",
keywords = "Amiodarone, Beta-blockers, Chronic heart failure, Digoxin, Heart rate, Heart rate-lowering drugs, Ivabradine, Verapamil",
author = "Daniela Dobre and Borer, {Jeffrey S.} and Kim Fox and Karl Swedberg and Adams, {Kirkwood F.} and Cleland, {John G F} and Alain Cohen-Solal and Mihai Gheorghiade and Francois Gueyffier and O'Connor, {Christopher M.} and Mona Fiuzat and Athul Patak and Pina, {Ileana L.} and Giuseppe Rosano and Sabbah, {Hani N.} and Luigi Tavazzi and Faiez Zannad",
year = "2014",
doi = "10.1093/eurjhf/hft129",
language = "English (US)",
volume = "16",
pages = "76--85",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Heart rate

T2 - A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

AU - Dobre, Daniela

AU - Borer, Jeffrey S.

AU - Fox, Kim

AU - Swedberg, Karl

AU - Adams, Kirkwood F.

AU - Cleland, John G F

AU - Cohen-Solal, Alain

AU - Gheorghiade, Mihai

AU - Gueyffier, Francois

AU - O'Connor, Christopher M.

AU - Fiuzat, Mona

AU - Patak, Athul

AU - Pina, Ileana L.

AU - Rosano, Giuseppe

AU - Sabbah, Hani N.

AU - Tavazzi, Luigi

AU - Zannad, Faiez

PY - 2014

Y1 - 2014

N2 - Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (riskfactor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bra-dycardic agent.

AB - Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (riskfactor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bra-dycardic agent.

KW - Amiodarone

KW - Beta-blockers

KW - Chronic heart failure

KW - Digoxin

KW - Heart rate

KW - Heart rate-lowering drugs

KW - Ivabradine

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=84896943402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896943402&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hft129

DO - 10.1093/eurjhf/hft129

M3 - Article

C2 - 23928650

AN - SCOPUS:84896943402

VL - 16

SP - 76

EP - 85

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 1

ER -